Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 14/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22885894 | 1.00 | HRH3 (0.59) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL18707030 | 1.00 | HRH3 (0.59) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL22101598 | 0.88 | HRH3 (0.51) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL21334459 | 0.86 | HRH3 (0.59) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL31081530 | 0.86 | HRH3 (0.59) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL20524367 | 0.85 | HRH3 (0.58) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL18706539 | 0.83 | HRH3 (0.53) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL21334463 | 0.82 | HRH3 (0.63) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL21093378 | 0.82 | HRH3 (0.56) | HRH3HDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL21093383 | 0.82 | HRH3 (0.56) | HRH3HDAC3HDAC4HDAC7HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398784-A1 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4408427-A1 | SYSTEM AND METHOD FOR STATIC AND DYNAMIC MRI SHIMMING | Merck Sharp & Dohme LLC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20230416225-A1 | DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-28 | — | — | US | disclosed |
| EP-3601284-B1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | HOFFMANN LA ROCHE (CH) | 2023-12-27 | — | — | EP | disclosed |
| CN-117024411-A | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110709392-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230295119-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GOSSAMER BIO SERVICES INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295119-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GOSSAMER BIO SERVICES INC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4240362-A1 | DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 | Merck Sharp & Dohme LLC (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023055679-A1 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-04-06 | — | — | WO | disclosed |
| EP-3394044-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| US-20180282282-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180282328-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2018183964-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018183956-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018109642-A1 | N-ARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| WO-2017106556-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
| WO-2017060854-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295119-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | IRAK3, TYK2, IRAK2 | HRH3 165/4885HDAC3 716/4885HDAC4 2200/4885 |
| US-20230416225-A1 | DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITORS OF HPK1 | PDXK, PHKG1, PHKG2 | HRH3 452/4885HDAC3 779/4885HDAC4 972/4885 |
| US-20180282282-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HIPK1, HPGDS, IP6K1 | HRH3 217/4885HDAC3 1591/4885HDAC4 1597/4885 |
| US-20180282328-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | NEK1, NEK5, NEK11 | HRH3 137/4885HDAC3 2434/4885HDAC4 1245/4885 |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | HRH3 4048/4885HDAC3 1503/4885HDAC4 2448/4885 |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | HRH3 1777/4885HDAC3 243/4885HDAC4 827/4885 |
| US-20240398784-A1 | C-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, BRSK2 | HRH3 675/4885HDAC3 1663/4885HDAC4 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.